The LRP6 rs2302685 polymorphism is associated with increased risk of myocardial infarction

Lipids in Health and Disease

Xing-dong Xiong³  Can Chen⁴  Xi-li Yang¹  Xinguang Liu³  Jin-ming Cen¹  Ze-wei Ma⁵  Keshen Li²  Yu-ning Chen³  Jie Cheng³  Shun Xu³ 

[1] Department of Cardiovascular Disease, The First People’s Hospital of Foshan, Foshan, P.R. China;Key Laboratory of Neurodegenerative Disease and Aging Research, Affiliated Hospital of Guangdong Medical College, Zhanjiang, P.R. China;Institute of Biochemistry & Molecular Biology, Guangdong Medical College, Zhanjiang, P.R. China;Department of Cardiovascular Disease, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, P.R. China;Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan, P.R. China

关键词: Risk;    Myocardial infarction;    Single nucleotide polymorphism;    LRP6;   

Others  :  801093
DOI  :  10.1186/1476-511X-13-94

 received in 2014-04-12, accepted in 2014-05-27,  发布年份 2014

【 摘 要 】

Background

Abnormal lipids is one of the critical risk factors for myocardial infarction (MI), however the role of genetic variants in lipid metabolism-related genes on MI pathogenesis still requires further investigation. We herein genotyped three SNPs (LRP6 rs2302685, LDLRAP1 rs6687605, SOAT1 rs13306731) in lipid metabolism-related genes, aimed to shed light on the influence of these SNPs on individual susceptibility to MI.

Methods

Genotyping of the three SNPs (rs2302685, rs6687605 and rs13306731) was performed in 285 MI cases and 650 control subjects using polymerase chain reaction–ligation detection reaction (PCR–LDR) method. The association of these SNPs with MI and lipid profiles was performed with SPSS software.

Results

Multivariate logistic regression analysis showed that C allele (OR = 1.62, P = 0.039) and the combined CT/CC genotype (OR = 1.67, P = 0.035) of LRP6 rs2302685 were associated with increased MI risk, while the other two SNPs had no significant effect. Further stratified analysis uncovered a more evident association with MI risk among younger subjects (≤60 years old). Fascinatingly, CT/CC genotype of rs2302685 conferred increased LDL-C levels compared to TT genotype (3.0 mmol/L vs 2.72 mmol/L) in younger subjects.

Conclusions

Our data provides the first evidence that LRP6 rs2302685 polymorphism is associated with an increased risk of MI in Chinese subjects, and the association is more evident among younger individuals, which probably due to the elevated LDL-C levels.

【 授权许可】

   
2014 Xu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, Keltai M, Diaz R, Rangarajan S, Yusuf S, Investigators I: Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008, 29:932-940.
• [2]Zhang XH, Lu ZL, Liu L: Coronary heart disease in China. Heart 2008, 94:1126-1131.
• [3]Donnan SP, Ho SC, Woo J, Wong SL, Woo KS, Tse CY, Chan KK, Kay CS, Cheung KO, Mak KH: Risk factors for acute myocardial infarction in a southern Chinese population. Ann Epidemiol 1994, 4:46-58.
• [4]Austin MA, Hutter CM, Zimmern RL, Humphries SE: Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004, 160:421-429.
• [5]Steinberg D: Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res 2005, 46:179-190.
• [6]Kallel A, Sediri Y, Sbai MH, Mourali MS, Feki M, Elasmi M, Taieb SH, Sanhaji H, Souheil O, Mechmeche R, Jemaa R, Kaabachi N: The paraoxonase L55M and Q192R gene polymorphisms and myocardial infarction in a Tunisian population. Clin Biochem 2010, 43:1461-1463.
• [7]Ghaderian SM, Akbarzadeh Najar R, Tabatabaei Panah AS: Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron Artery Dis 2010, 21:330-335.
• [8]Fujimaki T, Kato K, Yokoi K, Oguri M, Yoshida T, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Nozawa Y, Kimura G, Yamada Y: Association of genetic variants in SEMA3F, CLEC16A, LAMA3, and PCSK2 with myocardial infarction in Japanese individuals. Atherosclerosis 2010, 210:468-473.
• [9]Chen S, Bubeck D, MacDonald BT, Liang WX, Mao JH, Malinauskas T, Llorca O, Aricescu AR, Siebold C, He X, Jones EY: Structural and functional studies of LRP6 ectodomain reveal a platform for Wnt signaling. Dev Cell 2011, 21:848-861.
• [10]Liu CC, Prior J, Piwnica-Worms D, Bu G: LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci U S A 2010, 107:5136-5141.
• [11]Kokubu C, Heinzmann U, Kokubu T, Sakai N, Kubota T, Kawai M, Wahl MB, Galceran J, Grosschedl R, Ozono K, Imai K: Skeletal defects in ringelschwanz mutant mice reveal that Lrp6 is required for proper somitogenesis and osteogenesis. Development 2004, 131:5469-5480.
• [12]Manolagas SC, Almeida M: Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007, 21:2605-2614.
• [13]Clevers H, Nusse R: Wnt/beta-catenin signaling and disease. Cell 2012, 149:1192-1205.
• [14]Joiner DM, Ke J, Zhong Z, Xu HE, Williams BO: LRP5 and LRP6 in development and disease. Trends Endocrinol Metab 2013, 24:31-39.
• [15]Xu Y, Gong W, Peng J, Wang H, Huang J, Ding H, Wang DW: Functional analysis LRP6 novel mutations in patients with coronary artery disease. PLoS One 2014, 9:e84345.
• [16]Mani A, Radhakrishnan J, Wang H, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP: LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007, 315:1278-1282.
• [17]Keramati AR, Singh R, Lin A, Faramarzi S, Ye ZJ, Mane S, Tellides G, Lifton RP, Mani A: Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 2011, 108:1914-1918.
• [18]Zhao Z, Pompey S, Dong H, Weng J, Garuti R, Michaely P: S-nitrosylation of ARH is required for LDL uptake by the LDL receptor. J Lipid Res 2013, 54:1550-1559.
• [19]Garuti R, Jones C, Li WP, Michaely P, Herz J, Gerard RD, Cohen JC, Hobbs HH: The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem 2005, 280:40996-41004.
• [20]Mishra SK, Watkins SC, Traub LM: The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. Proc Natl Acad Sci U S A 2002, 99:16099-16104.
• [21]Kang RS, Folsch H: ARH cooperates with AP-1B in the exocytosis of LDLR in polarized epithelial cells. J Cell Biol 2011, 193:51-60.
• [22]Pisciotta L, Priore Oliva C, Pes GM, Di Scala L, Bellocchio A, Fresa R, Cantafora A, Arca M, Calandra S, Bertolini S: Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis 2006, 188:398-405.
• [23]Arca M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S, Calandra S, Ricci G, Glorioso N, Maioli M, Pintus P, Carru C, Cossu F, Cohen J, Hobbs HH: Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002, 359:841-847.
• [24]Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM: Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006, 354:1253-1263.
• [25]Rudel LL, Shelness GS: Cholesterol esters and atherosclerosis-a game of ACAT and mouse. Nat Med 2000, 6:1313-1314.
• [26]Sliskovic DR, Picard JA, Krause BR: ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis. Prog Med Chem 2002, 39:121-171.
• [27]Sediri Y, Kallel A, Feki M, Mourali S, Elasmi M, Abdessalem S, Mechmeche R, Jemaa R, Kaabachi N: Association of a DNA polymorphism of the apolipoprotein AI-CIII-AIV gene cluster with myocardial infarction in a Tunisian population. Eur J Intern Med 2011, 22:407-411.
• [28]Abd El-Aziz TA, Mohamed RH, Hashem RM: Association of lipoprotein lipase and apolipoprotein C-III genes polymorphism with acute myocardial infarction in diabetic patients. Mol Cell Biochem 2011, 354:141-150.
• [29]Izar MC, Helfenstein T, Ihara SS, Relvas WG, Santos AO, Fischer SC, Pinto LE, Lopes IE, Pomaro DR, Fonseca MI, Bodanese LC, Moriguchi EH, Saraiva JF, Introcaso L, Souza AD, Scartezini M, Torres KP, Zagury L, Jardim PC, Costa EA, Tacito LH, Forti A, Magalhaes ME, Chacra AR, Bertolami MC, Loures-Vale AA, Barros MA, Xavier HT, Lyra R, Argamanijan D, et al.: Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study. Atherosclerosis 2009, 204:165-170.
• [30]Lambert JC, Brousseau T, Defosse V, Evans A, Arveiler D, Ruidavets JB, Haas B, Cambou JP, Luc G, Ducimetiere P, Cambien F, Chartier-Harlin MC, Amouyel P: Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. Hum Mol Genet 2000, 9:57-61.
• [31]Xiong XD, Luo XP, Cheng J, Liu X, Li EM, Zeng LQ: A genetic variant in pre-miR-27a is associated with a reduced cervical cancer risk in southern Chinese women. Gynecol Oncol 2014, 132:450-454.
• [32]Wang JC, Normand SL, Mauri L, Kuntz RE: Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation 2004, 110:278-284.
• [33]De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, Myers A, Saez K, Henriquez JP, Zhao A, Wollmer MA, Nitsch RM, Hock C, Morris CM, Hardy J, Moon RT: Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A 2007, 104:9434-9439.
• [34]Sarzani R, Salvi F, Bordicchia M, Guerra F, Battistoni I, Pagliariccio G, Carbonari L, Dessi-Fulgheri P, Rappelli A: Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant. Nutr Metab Cardiovasc Dis 2011, 21:150-156.
• [35]Friedlander AH: Carotid artery calcifications are a risk indicator for both myocardial infarction and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol 2013, 115:700.
• [36]Hald EM, Lijfering WM, Mathiesen EB, Johnsen SH, Lochen ML, Njolstad I, Wilsgaard T, Rosendaal FR, Braekkan SK, Hansen JB: Carotid atherosclerosis predicts future myocardial infarction but not venous thromboembolism: the Tromso study. Arterioscler Thromb Vasc Biol 2014, 34:226-230.
• [37]Liu W, Mani S, Davis NR, Sarrafzadegan N, Kavathas PB, Mani A: Mutation in EGFP domain of LDL receptor-related protein 6 impairs cellular LDL clearance. Circ Res 2008, 103:1280-1288.
• [38]Tomaszewski M, Charchar FJ, Barnes T, Gawron-Kiszka M, Sedkowska A, Podolecka E, Kowalczyk J, Rathbone W, Kalarus Z, Grzeszczak W, Goodall AH, Samani NJ, Zukowska-Szczechowska E: A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterol. Arterioscler Thromb Vasc Biol 2009, 29:1316-1321.